Roldán-Marín R, Barreda-Becerril F, Toussaint-Cairec S, Piñeiro-Acosta E

Idioma: Español
Referencias bibliográficas: 29
Paginas: 61-64
Archivo PDF: 98.51 Kb.

RESUMEN

La eliminación transepidérmica es un mecanismo mediante el cual material extracelular o fibras alteradas de la dermis se eliminan a través de la epidermis. La elastosis perforante es un padecimiento raro caracterizado por eliminación transepidérmica de fibras elásticas alteradas. Clínicamente se manifiesta como pápulas queratósicas del color de la piel, que pueden confluir formando placas de aspecto arciforme o serpiginoso. Predomina en pacientes masculinos y menores de 30 años. Se presenta, hasta nuestro conocimiento, el primer caso de un paciente masculino con colitis ulcerativa crónica inespecífica y colangitis esclerosante asociadas a elastosis perforante.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Acquired disorders of elastic tissue: Part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol 2004;51:1-21.

2. Fujimoto N, Akagi A, Tajima S, Ishibashi A, Nombra K, Matsuhsita A, et al.Expression of the 67-kda elastin receptor in perforating skin disorders. Br J Dermatol 2002;146:74-79.

3. Lutz W. Keratosis follicularis serpiginosa. Dermatologica 1953;106:318.

4. Mehregan AH. Elastosis perforans serpiginosa: A review of the literature and report of 11 cases. Arch Dermatol 1968;97:381-393.

5. Wong KC, Fryer JA, Li M, Crosland G. Acquired perforating dermatosis in diabetes mellitus: An unusal case. Australas J Dermatol 1999;40:108-110.

6. Schamroth JM, Kellen P, Grieve TP. Elastosis perforans serpiginosa in a patient with renal disease. Arch Dermatol 1986;122:82-84.

7. Barr RJ, Siegel JM, Graham JH. Elastosis perforans serpiginosa associated with morphea. An example of “perforating morphea”. J Am Acad Dermatol 1980;3:19-22.

8. Iozumi K, Nakagawa H, Tamaki K. Penicillamine-induced degenerative dermatoses: Report of a case and brief review of such dermatoses. J Dermatol 1997;24:458-465.

9. Pass F, Goldfischer F, Sternlieb I, Scheinberg IH. Elastosis perforans serpiginosa during penicillamine therapy for Wilson’s disease. Arch Dermatol 1973;108:713-715.

10. Kirsch N, Hukill PB. Elastosis perforans serpiginosa induced by penicillamine.Arch Dermatol 1977;113:630-635.

11. Price RG, Prentice RS. Penicillamine-induce elastosis perforans serpiginosa.Tip of the iceberg? Am J Dermatopathol 1986;8:314-320.

12. Ratnavel RC, Norris PG. Penicillamine-induced elastosis perforans serpiginosa treated successfully with isotretinoin. Dermatology 1994;189:81-83.

13. Deguti MM, Mucemic M, Cancado EL, Tietge UJ. Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson’s disease patient. Am J Gastroenterol 2002;97:2153-2154.

14. Reymond JL, Stoebner P, Zambelli P, Beani JC, Amblard P. Penicillamine induced elastosis perforans serpiginosa: An ultrastructual study of two cases. J Cutan Pathol 1982;9:352-357.

15. Bardach H, Gebhart W, Niebauer G. “Lumpy-bumpy” elastic fibers in the skin and lungs of a patient with a penicillamine-induced elastosis perforans serpiginosa. J Cutan Pathol 1979;6:243-252.

16. Sahn EE, Maize JC, Garen PD, Mullins SC, Silver RM. D-penicillamineinduced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. Report of a case and review of the literature. J Am Acad Dermatol 1989;20:979-988.

17. Essigman WK. Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis. Ann Rheum Dis 1982;41:617-620.

18. Kahana M, Trau H, Dolev E, Schewach-Millet M, Gilon E. Perforating folliculitis in association with primary sclerosing cholangitis. Am J Dermatopathol 1985;7:271-276.

19. Mahajan S, Koranne RV, Sardana K, Mendiratta V, Damani A. Perforating folliculitis with jaundice in an Indian male: A rare case with sclerosing cholangitis. Br J Dermatol 2004;150:614-616.

20. Barrezueta-Chea S, Luis-Montoya P, Vega-Memije ME. Elastosis perforante serpiginosa: Reporte de un caso asociado con síndrome de Down y revisión de la bibliografía. Dermatología Rev Mex 2005;49:211-214.

21. Newman JS, Fung MA. Elastosis perforans serpiginosa in a patient with trisomy 21. Dermatol Online J 2006;12:5.

22. De Pasquale R, Nasca MR, Musumeci ML, Micali G. Elastosis perforans serpiginosa in an adult with Down’s syndrome: Report of a case with symmetrical localized involvement. J Eur Acad Dermatol Venereol 2002;16:387-389.

23. Jan V, Saugier J, Arbeille B, Maurage C, Callens A, Lorette G. Elastosis perforans serpiginosa with vitamin A deficiency in a child with trisomy 21. Ann Dermatol Venereol 1996;123:188-190.

24. Scherbenske JM, Benson PM, Rotchford JP, James WD. Cutaneous and ocular manifestations of Down syndrome. J Am Acad Dermatol 1990;22:933- 938.

25. Patterson JW. The perforating disorders. J Am Acad Dermatol 1984;10:561-581.

26. Mehta RK, Burrows NP, Payne CM, Mendelsohn SS, Pope FM, Rytina E.Elastosis perforans serpiginosa and associated disorders. Clin Exp Dermatol 2001;26-521-524.

27. Outland JD, Brown TS, Callen JP. Tazarotene is an effective therapy for elastosis perforans serpiginosa. Arch Dermatol 2002;138:169-171.

28. Tuyp EJ, mcleod WA. Elastosis perforans serpiginosa: Treatment with liquid nitrogen. Int J Dermatol 1990;29:655-656.

29. Rosenblum GA. Liquid nitrogen cryotherapy in a case of elastosis perforans serpiginosa. J Am Acad Dermatol 1983;8:718-721.